Vaccine Delivery Devices Market to Reach $1.5 Billion by 2030 | Becton Dickinson, Inovio Pharmaceuticals, PharmaJet Among Key Players

The global vaccine delivery devices market is on track to reach $1.5 billion by 2030, according to the latest market intelligence report published by Roots Analysis. The market's expansion is driven by accelerating global vaccination coverage, now nearing 85% worldwide, and mounting demand for needle-free, self-administered, and cold-chain-independent delivery formats. With the global vaccines market projected to generate $100 billion in revenues by 2025, the devices that deliver those vaccines are becoming a critical commercial and public health priority.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/vaccine-delivery-devices/request-sample.html

Market Overview
Vaccine delivery devices are a specialized category of drug delivery technology designed for the convenient, accurate, and safe administration of vaccines and biological products. The traditional parenteral route, primarily intramuscular and subcutaneous injection, has served as the backbone of global immunization for decades. However, the limitations of needle-based administration are forcing a systematic reconsideration of how vaccines reach patients. Pain during injection, needlestick injury risk, cross-contamination potential, and inaccurate dosing under field conditions are well-documented drawbacks. Beyond clinical concerns, trypanophobia, or needle fear, remains a significant barrier to voluntary immunization in many populations.

These constraints have created strong market and policy pull toward non-invasive delivery formats. Oral, intranasal, and transdermal routes are now attracting serious investment from biopharmaceutical companies and research institutions alike. The WHO's immunization data shows that more than 115 million children were vaccinated against diphtheria, tetanus, and pertussis in 2018 alone, underscoring the enormous volume and logistical complexity of global immunization campaigns. Devices that simplify large-scale administration, reduce dependence on trained healthcare workers, and eliminate cold chain requirements are not a niche aspiration; they are an operational necessity for health systems managing mass immunization events.

Recent deal activity confirms that the sector is attracting capital at pace. In January 2026, Pfizer entered into a licensing agreement with Novavax valued at up to $530 million covering Matrix-M adjuvant technology used in vaccine delivery. In November 2025, Dynavax licensed Vaxart's oral COVID-19 vaccine program for $25 million upfront plus a $5 million equity stake. That same year, Apiject Systems submitted a New Drug Application to the FDA for the world's first single-dose, single-use prefilled plastic syringe injection device. These are not speculative bets; they are commercial commitments by major industry players.

Key Growth Drivers
Rising Global Immunization Coverage and Population Growth. The WHO estimates that current global vaccination coverage prevents close to three million deaths annually from diseases including diphtheria, tetanus, whooping cough, and measles. As population growth and new disease threats expand the volume of vaccines required, delivery systems capable of meeting that scale efficiently are in direct commercial demand.

Shift Toward Non-Invasive and Self-Administration Formats. Biopharmaceutical developers and clinical researchers are actively building delivery pipelines around oral, intranasal, and transdermal routes. These formats reduce dependency on trained clinical staff, lower infection risk, and expand the viability of self-administration. Companies are integrating features such as audio and visual feedback, disposable formats, and needleless mechanisms to make these products suitable for decentralized immunization.

Pandemic Preparedness and Mass Immunization Readiness. The COVID-19 experience exposed the logistical fragility of conventional vaccine distribution. Medical centers in many regions were not equipped to handle rapid, large-scale immunization campaigns using parenteral methods. Novel delivery devices, particularly those that eliminate cold chain dependence and support self-administration, directly address this gap and are now embedded in government procurement planning globally.

Active Corporate Dealmaking and Technology Licensing. The pace of partnerships, licensing agreements, and equity investments in vaccine delivery technology has accelerated materially since 2020. Roots Analysis has tracked deals focused on a diverse range of device types involving both international and domestic stakeholders, reflecting a competitive race to establish IP positions and commercial supply agreements ahead of the next major immunization cycle.

Pipeline Depth Across 130-Plus Devices. Over 130 unique novel vaccine delivery devices are currently marketed or under active development. Close to 500 vaccine candidates are being evaluated in combination with these novel systems. This pipeline depth reflects a structural increase in development activity, not a transient spike, and it provides a long runway for market growth through and beyond the 2030 forecast horizon.

Market Segmentation
The vaccine delivery devices market segments by type of device, route of administration, vaccine type, and geography. By device type, the market covers needle-free injection systems, oral delivery systems, nasal delivery systems, jet injectors, microneedle patches, and microinjectors. Electroporation-based needle-free injection systems represent a technically advanced category attracting dedicated R&D investment, while microneedle patches and nasal delivery systems are gaining traction for their self-administration potential and patient-friendly profiles. The oral delivery segment is particularly notable given its applicability to mass immunization programs targeting pediatric populations.

By route of administration, the market spans oral, intramuscular, intranasal, intradermal, and subcutaneous pathways. While intramuscular delivery currently holds the largest base given its use in established vaccine programs for influenza, DTP-HepB-Hib, and pneumococcal products, the intranasal and oral routes are registering the strongest development activity among novel device categories. Geographically, North America, Europe, Asia, and the rest of the world are the primary segments, with the US serving as the current hub for vaccine delivery focused firms.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/vaccine-delivery-devices/request-quote.html

Regional Insights
North America holds the leading position in the global vaccine delivery devices market, supported by the concentration of major device developers, strong FDA regulatory infrastructure, and high public and private investment in pandemic preparedness. The US is home to a disproportionate share of the over 75 companies currently active in this market, and recent FDA submissions, including Apiject Systems' New Drug Application for its prefilled syringe device in September 2025, demonstrate that the regulatory pipeline remains active.

Europe is a significant and growing market, with collaborative development programs actively underway. In February 2026, SK bioscience, IDT Biologika, and Vaxxas announced a joint project targeting the premium European seasonal influenza vaccine market for older adults using advanced delivery technologies. This initiative reflects the region's dual focus on innovation and its aging demographic as a driver of next-generation device demand. Asia represents the fastest-growing regional opportunity, driven by high population density, expanding national immunization programs, and increasing government investment in domestic vaccine manufacturing and delivery infrastructure.

Competitive Landscape
Key companies profiled in the Roots Analysis vaccine delivery devices market report include 3M, Becton Dickinson, Consort Medical, D'Antonio Consultants International, Enesi Pharma, Ichor Medical Systems, Iconovo, Inovio Pharmaceuticals, PharmaJet, and Union Medico, among others. The full report contains an excel-searchable database of all companies active in the space globally.

The competitive field is fragmented, featuring both established medical device companies with broad commercial infrastructure and smaller, technology-focused entrants holding proprietary IP in specific delivery mechanisms. The primary battleground is not pricing but technology differentiation; companies are competing on route of administration capabilities, self-administration design, cold-chain independence, and the depth of their clinical evidence base. Licensing activity, as seen in the Pfizer-Novavax and Dynavax-Vaxart deals, suggests that larger players are increasingly opting to acquire or license novel delivery technologies rather than develop them independently from scratch.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/vaccine-delivery-devices/280.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.